Biotech Related Topics 
TechCrunch
FEBRUARY 25, 2023
Biotech was one of the most fortunate. Those figures fell short of the 1,415 biotech deals struck in 2021 worth a total of $39 billion. Compared to 2020’s more conservative 1,143 biotech deals worth $29.6 biotech deals also set new records in 2022 for both median deal size, $33.5 The sector recorded 1,054 U.S.-based
TechCrunch
DECEMBER 15, 2022
JP Morgan’s announcement comes at a time when, in the words of B Capital general partner and head of healthcare Robert Mittendorff M.D, “public market biotechs are dramatically down as interest rates rise and the focus on near-term development outweighs the promise of longer-term results and approvals.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
TechCrunch
DECEMBER 15, 2022
That’s why we weren’t very surprised when a slew of investors told us they rarely see a biotech startup that doesn’t incorporate AI in some form or other these days. But despite becoming quite the buzzword, AI’s apparent ubiquity in biotech isn’t actually driving deal flow or higher valuations.
TechCrunch
MARCH 16, 2023
More posts by this contributor 3 tips for biotech startups seeking non-dilutive capital to weather the downturn Founders in the biotech industry are no strangers to challenges. This is especially true for biotech startups, where investment needs are higher and success timelines can be much longer.
TechCrunch
APRIL 6, 2022
But the path won’t be easy: Many biotech companies working with psychedelic compounds must complete multiyear clinical trials that can cost over $100 million before winning FDA approval, similar to any other biotech company. The most important factor that can make or break a psychedelic biotech company is its team.
TechCrunch
DECEMBER 7, 2023
A new Seattle biotech organization will be funded to the tune of $75 million to research “DNA typewriters,” self-monitoring cells that could upend our understanding of biology. The collaboration between the University of Washington, the Chan-Zuckerberg Initiative and the Allen Institute is already underway.
TechCrunch
OCTOBER 28, 2022
In the world of biotech, for example, it’s extremely capital intensive to develop multiple products that are all going through clinical trials simultaneously. 5 ways biotech startups can mitigate risk to grow sustainably in the long run by Ram Iyer originally published on TechCrunch.
Expert insights. Personalized for you.
237 
Let's personalize your content